Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Heart Failure 3Lymphoma, Follicular 2Cardiotoxicity 2Breast Neoplasms 2Thyroid cancer, medullary 1Renal Insufficiency 1Neoplasms, Second Primary 1Neoplasms 1Hypertension 1Carcinoma, Medullary 1Breast Diseases 1

Interventions

Rituximab 295Cyclophosphamide 240Peripheral Blood Stem Cell Transplantation 114fludarabine phosphate 110Filgrastim 93Etoposide 85Radiotherapy 81Lenalidomide 79Vincristine 78Prednisone 77Mycophenolic Acid 66Doxorubicin 61Cyclosporine 59Whole-Body Irradiation 58Bendamustine Hydrochloride 58Melphalan 57Tacrolimus 53Busulfan 51fludarabine 50Cytarabine 48obinutuzumab 46Methotrexate 45Antilymphocyte Serum 43Bortezomib 42Methylprednisolone 37Carmustine 37sargramostim 36ibritumomab tiuxetan 32ibrutinib 30Dexamethasone 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Lymphoma, Follicular × sacubitril and valsartan sodium hydrate drug combination × Clear all
NCT06236061 2026-01-13

Study of Efficacy and Safety of LCZ696/Amlodipine in Grade 1 and 2 Hypertension Patients Uncontrolled by LCZ696 Monotherapy

Novartis

Phase 3 Completed
718 enrolled
Lymphoid

Hypertension, Lymphoma, Follicular

NCT01569815 2015-10-19

Pharmacokinetics of LCZ696 in Subjects With Mild and Moderate Renal Impairment Compared to Healthy Subjects With Normal Renal Function

Novartis

Phase 1 Completed
32 enrolled 16 charts
Lymphoid

Lymphoma, Follicular, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡